ArticleThe American journal of case reports2026
Cocaine-Levamisole-Associated Vasculopathy Mimicking ANCA-Associated Vasculitis and Presenting With Pulmonary-Renal Syndrome Requiring VV-ECMO Support.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Levamisole, a widely used adulterant in illicit cocaine, has emerged as an important cause of cocaine-levamisole-associated vasculopathy (CLAV), a syndrome that can mimic primary ANCA-associated vasculitis. Typical features include neutropenia, atypical ANCA patterns, thrombotic manifestations, diffuse alveolar hemorrhage (DAH), and crescentic glomerulonephritis (GN). Dual MPO-PR3 ANCA positivity is strongly suggestive of drug-induced vasculopathy. CASE REPORT We report the case of a 30-year-old woman presenting with hemoptysis, anemia, and diffuse pulmonary infiltrates. Laboratory evaluation demonstrated hematuria, proteinuria, and dual MPO/PR3 ANCA positivity. Renal biopsy showed necrotizing crescentic GN, and urine toxicology confirmed cocaine exposure. She received pulse corticosteroids and rituximab. Three days after early discharge, she returned with massive hemoptysis and respiratory failure. Bronchoscopy confirmed DAH, and arterial blood gases demonstrated refractory hypoxemia with a PaO2/FiO2 ratio below 80 despite maximal ventilatory support. Plasmapheresis was initiated, followed by veno-venous extracorporeal membrane oxygenation (VV-ECMO) for worsening respiratory acidosis and persistent hypoxemia. Cyclophosphamide was added when her condition stabilized. Her respiratory status gradually improved, she was decannulated from ECMO, and renal function normalized. At 18 months, she remained in remission with minimal residual pulmonary abnormalities despite persistent MPO-ANCA positivity. CONCLUSIONS This case highlights CLAV as a severe vasculopathic mimic of ANCA-associated vasculitis. Early recognition, cessation of cocaine use, appropriate immunosuppression, and timely escalation to VV-ECMO when indicated are critical for survival in fulminant DAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.